Around 10,000 people set to take part in clinical trials from Covid-19 vaccine maker
The UK government has signed a deal with German Covid-19 vaccine maker BioNTech to speed up clinical trials for cancer vaccines.
BioNTech, which developed one of the world’s most-used Covid-19 vaccines with US pharmaceutical group Pfizer, said the agreement could result in around 10,000 UK patients receiving cancer vaccines by the end of 2030, either in clinical trails or as an authorised treatment.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.